Auteur: Neville Nicholson

Stephen K. Wrigley has worked in the field of industrial natural products drug discovery and development for twenty five years. He is currently Chief Technical Officer at Hypha Discovery Ltd., where his scientific interests are focused on the identification and evaluation of novel basidiomycete metabolites with anticancer and antimicrobial activities. Prior to joining Hypha, he led efforts to characterize and develop new lipopeptide antibiotics at Recombino Gen Ltd. Steve was formerly Senior Director of Research for Cubist Pharmaceuticals (UK) Ltd., where he led a team engaged in antibiotic screening and participated in programmes to generate improved lipopeptides through chemical and genetic modification. He had previously held research management and scientific positions involving microbial product discovery at Terra Gen Discovery, Inc., Xenova Ltd. and Glaxo Group Research Ltd. Steve obtained BSc and Ph D degrees, both in chemistry, from Imperial College, University of London, in 1982 and 1985, respectively.